advertisement
Abstract #11408 Published in IGR 6-3
Increase in outflow facility with unoprostone treatment in ocular hypertensive patients
Toris CB; Zhan G; Camras CBArchives of Ophthalmology 2004; 122: 1782-1787
OBJECTIVE: To determine the mechanism by which 0.15% unoprostone isopropyl reduces intraocular pressure (IOP) by studying 33 patients with ocular hypertension or primary open-angle glaucoma. METHODS: At baseline, IOP was determined by pneumatonometry, aqueous flow and outflow facility by fluorophotometry, episcleral venous pressure by venomanometry, and uveoscleral outflow by mathematical calculation. Unoprostone was administered to one eye and placebo to the fellow eye of each patient twice daily in a randomized masked fashion. In patients who demonstrated an IOP reduction of 3 mmHg or more in either eye on day 5 ± 1 (n = 29), determinations were repeated on that day and on day 28 ± 2. Treated eyes were compared with control eyes, and treatment days were compared with baseline by paired t tests. RESULTS: Compared with baseline, unoprostone significantly (P<.001) reduced IOP by a mean ± SEM of 5.6 ± 0.4 mmHg and 4.8 ± 0.6 mmHg on days 5 and 28, respectively. The change from baseline with unoprostone was significantly (P < .001) greater than with placebo by 2.8 ± 0.4 mmHg on day 5 and by 3.2 ± 0.5 mmHg on day 28. Compared with baseline, unoprostone significantly (P ≤ .001) increased outflow facility by 0.05 ± 0.01 and 0.08 ± 0.02 μL.min-1.mmHg-1 on days 5 and 28, respectively. The baseline-adjusted between-treatment differences were significant (P ≤ .04) on day 28 (0.06 ± 0.02 μL.min-1.mmHg-1). Other measures were not different from placebo. CONCLUSION: In responsive patients, unoprostone decreased IOP by increasing outflow facility.
Dr. C. Toris, Department of Ophthalmology, University of Nebraska Medical Center, Omaha 68198-5840, USA. ctoris@unmc.edu
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
